Clinical bottom line
Allergic reactions to biologic therapies in allergy practice, while uncommon, pose diagnostic and management challenges that require heightened clinician awareness. Early recognition of hypersensitivity manifestations—including immediate and delayed reactions—is essential to optimize patient safety and treatment continuity. Current evidence underscores the importance of standardized diagnostic approaches, including clinical assessment and selective use of in vitro and in vivo testing, although validated protocols remain limited. Management strategies emphasize risk stratification, premedication, desensitization protocols, and alternative biologic selection when appropriate. Ongoing vigilance and individualized care plans are warranted given evolving biologic indications and expanding patient populations.
What the evidence shows
Biologic therapies targeting IgE, interleukins, and other immune pathways have transformed allergy treatment paradigms, particularly in severe asthma and nasal polyposis (Gyawali et al., 2025; Geng et al., 2021). Despite their generally favorable safety profiles, allergic reactions can occur, ranging from mild infusion-related symptoms to severe anaphylaxis. The incidence of hypersensitivity reactions varies by agent and patient population but remains relatively low compared to traditional systemic therapies (Gyawali et al., 2025).
Immediate hypersensitivity reactions typically manifest within minutes to hours of administration and may include urticaria, angioedema, bronchospasm, and anaphylaxis. Delayed reactions, though less common, can present as serum sickness-like syndromes or delayed rash (Eisenberg et al., 2016). The pathophysiology involves IgE-mediated mechanisms, complement activation, or non-IgE-mediated mast cell activation, underscoring the heterogeneity of these events (Allergy in Practice).
Diagnostic evaluation relies primarily on detailed clinical history and timing relative to biologic exposure. Skin testing and serum-specific IgE assays have been employed but lack standardized sensitivity and specificity for many biologics (Hamilton et al., 2010). In vitro basophil activation tests and drug provocation tests may aid diagnosis but are not widely available or validated for routine use (Eisenberg et al., 2016).
Management strategies include premedication with antihistamines and corticosteroids to mitigate mild reactions, temporary discontinuation, and, in select cases, rapid desensitization protocols that allow continuation of essential biologic therapy (Gyawali et al., 2025). Switching to alternative biologics with different molecular targets or formulations may be necessary if reactions recur or are severe (Geng et al., 2021). Multidisciplinary collaboration involving allergists, pulmonologists, and pharmacists is critical for individualized risk assessment and management.
Caveats and uncertainty
The evidence base for allergic reaction diagnosis and management specific to biologics in allergy practice remains limited by small cohort sizes, heterogeneous reporting, and lack of randomized controlled trials. Most data derive from observational studies or extrapolation from oncology and rheumatology biologic use. Diagnostic tests such as skin testing and basophil activation assays lack standardized protocols and validation for many allergy biologics, limiting their clinical utility.
Furthermore, the expanding repertoire of biologics with novel targets and formulations introduces new potential hypersensitivity mechanisms that are not yet fully understood. Long-term safety data on repeated exposures and desensitization protocols are sparse. Variability in patient immune status, concomitant medications, and comorbidities further complicate risk prediction.
Therefore, current recommendations are largely consensus-based and hypothesis-generating, emphasizing the need for prospective studies and registries to better characterize incidence, mechanisms, and optimal management strategies.
How this may change practice
Clinicians should maintain a high index of suspicion for allergic reactions during biologic therapy administration and incorporate systematic assessment protocols into practice. Early recognition and prompt management can prevent progression to severe reactions and allow safe continuation of therapy when possible.
Implementation of standardized clinical pathways for evaluation—including detailed history, timing correlation, and selective testing—may improve diagnostic accuracy. Premedication and desensitization protocols should be considered in patients with mild to moderate reactions to maintain access to effective biologics.
Education of patients regarding potential signs of hypersensitivity and emergency response plans is essential. Collaboration with allergy specialists for complex cases will enhance individualized care.
As biologic indications broaden and new agents emerge, ongoing surveillance and research into hypersensitivity mechanisms and management will be critical to optimize safety and therapeutic outcomes.